Diego Preciado Diego Preciado
Professor of Surgery
Professor of Pediatrics (Secondary)
Professor of Genomics and Precision Medicine (Third)

Office Phone: 202-884-3659
Email: Email
Department: Surgery


  • BS, Georgetown University, 1992
  • MD, University of Minnesota, 1997
  • PhD, University of Minnesota, 2006


I am a board certified pediatric otolaryngologist, with a busy clinical practice focused on childhood hearing loss and airway reconstruction. I am lead surgeon and director of a busy pediatric cochlear implant team. An active basic science researcher, I have also long been keenly intrigued by how unregulated inflammation, specifically through intracellular pro-inflammatory transcription factor pathways, appears to be a central feature of multiple cancerous and non-cancerous diseases. Ever since medical school I have had an interest and career goal of becoming a physician-scientist with an independently funded translational laboratory.  I have been extremely fortunate to be able to expand on this interest with outstanding basic science and clinical mentors. In the lab, I have sought to learn how pathologically relevant agents, most often inflammatory, result in cellular events that contribute to chronic ear infections. The long-term goals of my research are to contribute to a greater understanding of human otitis media and provide data to guide future investigations into the development of medical treatments to prevent or help resolve middle ear effusion in humans, which treatments currently do not exist.

Additional Education

Residency, U of MN Dept of Otolaryngology, Minneapolis, MN 1998-2002 Otolaryngology
Pediatric Otolaryngology Fellowship, Cincinnati, OH 2002-2004 Ped. Otolaryngology



  • Block BB, Kuo E, Zalzal HG, Escobar H, Rose M, Preciado D. In vitro effects of acid and pepsin on mouse middle ear epithelial cell viability and MUC5B gene expression. Arch Otolaryngol Head Neck Surg. 2010 Jan;136(1):37-42.
  • Juhn SK, Jung MK, Hoffman MD, Drew BR, Preciado DA, Sausen NJ, Jung TT, Kim BH, Park SY, Lin J, Ondrey FG, Mains DR, Huang T. The role of inflammatory mediators in the pathogenesis of otitis media and sequelae. Clin Exp Otorhinolaryngol. 2008 Sep;1(3):117-38.
  • Johnston B, Preciado D, Ondrey F, Daly K.  Presence of Otitis Media with Effusion and its Risk Factors Affect Serum Cytokine Profile in Children. Int J of Ped Otorhinolaryngology. 2008 Feb;72(2):209-14.
  • Preciado D, Lin J, Wuertz B, Rose MC. Cigarette Smoke Activates NF-kappaB and Induces Muc5b Expression in Mouse Middle Ear Cells.  Laryngoscope. . 2008 Mar;118(3):464-71
  • Preciado DA, Caicedo E, Jhanjee R, Silver R, Harris G, Juhn SK, Choo DI, Ondrey FG.  Pseudomonas aeruginosa lipopolysaccharide induction of keratinocyte proliferation, NF?-B, and cyclin D1 is inhibited by indomethacin. Journal of Immunology. 2005 Mar 1;174(5):2964-73


  • Chun R, Preciado DA, Zalzal GH, Shah RK. Utility of bronchoscopy for recurrent croup. Ann Otol Rhinol Laryngol. 2009 Jul;118(7):495-9.
  • Ryan JT, Preciado DA, Bauman N, Pena M, Bose S, Zalzal GH, Choi S. Management  of pediatric orbital cellulitis in patients with radiographic findings of subperiosteal abscess. Otolaryngol Head Neck Surg. 2009 Jun;140(6):907-11.
  • Preciado DA, Zalzal GH.  Laryngeal and tracheal stents in children. Curr Opin Otolaryngol Head Neck Surg. 2008 Feb;16(1):83-5.
  • White DR, Preciado DA, Stamper B, Willging JP, Myer CM 3rd, Cotton RT, Rutter MJ.  Airway Reconstruction in Pediatric Burn Patients. Otolaryngol Head Neck Surg. 2005 Sep;133(3):362-365.
  • Preciado DA, Lawson L, Madden C, Myer D, Ngo C, Bradshaw JK, Choo DL, Greinwald JH. Improved Diagnostic Effectiveness with a Sequential Diagnostic Paradigm in Idiopathic Pediatric Sensorineural Hearing Loss.  Otol Neurotol. 26(4):610-615, 2005.


Otitis Media (OM): Since my transition to CNMC I really have focused on OM, as inflammation clearly is a central feature in the progression of this disease from acute to chronic. Mucus hypersecretion is one of the characteristic phenotypes and Dr. Mary C. Rose, a world re-known leader in the mucin glycoprotein field, is in the Center for Genetic Medicine Research at CNMC. Dr. Rose has provided mentorship to me since I relocated to CNMC.  I have set up my laboratory immediately adjacent to hers and function directly as part of her lab team. OM is a multifactorial disease with many environmental agents being pathologically relevant. Through mentored research awards, we have begun to analyze effects of cigarette smoke products, bacterial agents, and supraesophageal reflux on mucin genes in vitro. Ultimately we hope to contribute meaningfully to the development of novel treatments in this exceedingly common disease.    

Sensorineural Hearing Loss: As part of our cochlear implant (CI) program, we are attempting to develop strategies to measure outcomes after CI. This will be critical to better predict clinical success and will be extremely useful for parental expectation education, surgical candidacy decision making, and risk-stratified outcomes assessments. We also want to determine whether certain individual patient characteristics can predict worse neuropsychological or language outcomes. Also, we are under the impression that although language may not be improved significantly in our older prelingually hearing impaired recipients, the ability to have sound awareness conferred by the device does allow them some potential neuropsychological benefit. This supposition is being assessed empirically and methodically. Finally, we serve a large portion of minority (largely Hispanic) families, where the implanted children are receiving speech therapy in English, most often a second language to their parents.  Whether their ultimate language outcome is different than same language (rehabilitation-home) recipient families remains controversial and is being studied. 

Infantile Hemangiomas: Infantile hemangiomas represent the most common tumor of infancy, affecting up to 10% of children. These benign tumors can vary significantly in their localization and extent of soft tissue involvement, but their biological progression is remarkably unique and predictable. Recently, propranolol was reported to be effective in treating infantile hemangiomas in a small patient series. Propranolol is rapidly becoming a widespread form of medical treatment to the point it may surpass prednisone as a preferred treatment mode. The molecular mechanism by which propranolol works in patients with infantile hemangiomas is unknown. In conjunction with Dr. Nancy Bauman,  a prospective, randomized trial has been set up to compare the effectiveness of propanalol vs. corticosteroids for the treatment of infantile hemangiomas. As a translational basic science aim, we are hoping to characterize the transcriptome of these lesions. Notably, no studies have been performed that have utilized genome wide, large scale expression array technology to determine if there are any differences in infantile hemangiomas by clinical extensiveness and likelihood to respond to medical treatment. The hypothesis to be tested herein is that genome wide expression arrays will demonstrate a distinct profile of genes depending on the lesions’ clinical extensiveness and on their responsiveness to medical treatment.

Link to pubmed publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=preciado+d

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • None